The rules for designing cyclic peptides with drug-like properties are unclear. Two studies now show how cyclic peptide libraries can be created to optimize properties such as cell permeability before screening for binding activity. The approach has led to a macrocyclic peptide inhibitor for KRAS that has reached clinical trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Buyanova, M. & Pei, D. Trends Pharmacol. Sci. 43, 234–248 (2022).
Ji, X., Nielsen, A. L. & Heinis, C. Angew. Chem. Int. Ed. 63, e202308251 (2023).
Vinogradov, A. A., Yin, Y. & Suga, H. J. Am. Chem. Soc. 141, 4167–4181 (2019).
Tanada, M. et al. J. Am. Chem. Soc. 145, 16610–16620 (2023).
Ohta, A. et al. J. Am. Chem. Soc. 145, 24035–24051 (2023).
Hillig, R. C. et al. Proc. Natl Acad. Sci. 116, 2551–2560 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Pal, S., ‘t Hart, P. Imbuing peptide libraries with drug-likeness. Nat Chem Biol 20, 140–141 (2024). https://doi.org/10.1038/s41589-023-01524-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-023-01524-x
